There was a flurry of clinical reports at the end of the week. Some of the more significant ones follow - as always based on my criteria for significance.
Pharmaceutical Business Review reported the Novartis' Tasigna (nilotinib) treatment for Philadelphia chromosome positive CLL received priority review status from the FDA.
Also in PBR VIRxSys reported results from its recent HIV vaccine (VRX1023) study in Rhesus monkeys. The lentiviral based vaccine elicited high levels of CD107, an important element in Tcell immune response to HIV. No adverse reactions were observed in test animals.
As reported in Silobreaker, Genentech's blockbuster Rituxan (rituximab) was approved a new indication in the treatment of CLL, the second most common leukemia in adults.
Posted by Bruce Lehr Feb 19, 2010